Literature DB >> 9384666

The TNF ligand superfamily and its relevance for human diseases.

H J Gruss1, S K Dower.   

Abstract

The tumor necrosis factor (TNF) receptor superfamily comprises 10 different members of type I integral membrane glycoproteins with characteristic limited sequence homology for the extracellular cysteine-rich repeats. A parallel existing TNF ligand superfamily has been discovered by cloning of ligands for all of the TNF receptor superfamily members. These molecules are type II membrane glycoproteins, with the exception of LT-alpha, which is the only secreted protein of the family. TNF and CD95L also exist in biologically active shed soluble form. The TNF ligand superfamily presently contains nine different proteins. In addition, the NGFR p75 binds to a second family of proteins. These NGF-like dimeric soluble molecules are basic neurotrophic factors, and the five members are not related to the TNF superfamily ligands. The TNF-like ligands share some common biological activities, but other activities appear to be shared only by some ligands or are unique. The diverse biological effects mediated through the interaction of the members of the TNF receptor and ligand superfamilies have provided information on the regulation of cellular activation, including the involvement of T-cell-dependent immune responses as well as associations with human diseases.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 9384666

Source DB:  PubMed          Journal:  Cytokines Mol Ther        ISSN: 1355-6568


  13 in total

1.  Nitric oxide potentiates TNF-α-induced neurotoxicity through suppression of NF-κB.

Authors:  Atsuko Nakaizumi; Taeko Horie; Teruyo Kida; Takuji Kurimoto; Tetsuya Sugiyama; Tsunehiko Ikeda; Hidehiro Oku
Journal:  Cell Mol Neurobiol       Date:  2011-07-21       Impact factor: 5.046

Review 2.  New peptide and protein drugs.

Authors:  P Vermeij; D Blok
Journal:  Pharm World Sci       Date:  1996-06

Review 3.  A primer on cytokines: sources, receptors, effects, and inducers.

Authors:  J H Curfs; J F Meis; J A Hoogkamp-Korstanje
Journal:  Clin Microbiol Rev       Date:  1997-10       Impact factor: 26.132

Review 4.  Neurotrophin strategies for neuroprotection: are they sufficient?

Authors:  Joseph P Steiner; Avindra Nath
Journal:  J Neuroimmune Pharmacol       Date:  2014-03-08       Impact factor: 4.147

5.  CD40 ligand expression on the surface of colostral T cells.

Authors:  A Bertotto; G Castellucci; M Radicioni; M Bartolucci; R Vaccaro
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1996-03       Impact factor: 5.747

6.  Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice.

Authors:  K Tomita; G Tamiya; S Ando; K Ohsumi; T Chiyo; A Mizutani; N Kitamura; K Toda; T Kaneko; Y Horie; J-Y Han; S Kato; M Shimoda; Y Oike; M Tomizawa; S Makino; T Ohkura; H Saito; N Kumagai; H Nagata; H Ishii; T Hibi
Journal:  Gut       Date:  2005-09-20       Impact factor: 23.059

Review 7.  Structure-based design of immunologically active therapeutic peptides.

Authors:  R Murali; M I Greene
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

Review 8.  The promise and challenges of immune agonist antibody development in cancer.

Authors:  Patrick A Mayes; Kenneth W Hance; Axel Hoos
Journal:  Nat Rev Drug Discov       Date:  2018-06-15       Impact factor: 84.694

Review 9.  Control of arthritis pain with anti-nerve-growth factor: risk and benefit.

Authors:  Matthias F Seidel; Nancy E Lane
Journal:  Curr Rheumatol Rep       Date:  2012-12       Impact factor: 4.592

10.  The safety of etanercept for the treatment of plaque psoriasis.

Authors:  Kim A Papp
Journal:  Ther Clin Risk Manag       Date:  2007-06       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.